Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease
NCT ID: NCT05157139
Last Updated: 2022-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
120 participants
INTERVENTIONAL
2021-11-01
2022-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* The study aims to treat people with mild-to-moderate COVID-19 before their cases become severe.
* The study duration is a 5-day experimental intervention and an extended 4 weeks follow up.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Patients receiving only standard care
No interventions assigned to this group
Intervention (low dose)
Two capsules twice daily for 3 days then one capsule twice daily for 2 days
Oral Capsule
Oral Capsule of vanillin \& wheat germ oil
Intervention (high dose)
two capsules three times daily for 3 days, followed by one capsule three times daily for 4 days
Oral Capsule
Oral Capsule of vanillin \& wheat germ oil
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral Capsule
Oral Capsule of vanillin \& wheat germ oil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥18 years.
3. Both genders
4. The disease started within 7 days (ideally 72 hours) of diagnosis or clinical deterioration.
5. Patients diagnosed as mild or moderate
Exclusion Criteria
2. General: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation, and advanced cardiovascular diseases.
3. Allergy to Vanilla flavor, vanillin, or wheat germ oil
4. Active cancer
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assoc. Prof. Ayman Ibrahim Baess
UNKNOWN
Dr. Noha Alaa Eldine Hassan Hamdy
UNKNOWN
Ph. Hanya Hesham Sweilam
UNKNOWN
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Ibrahim ElMallah
Professor of Pharmacology & Therapeutics, Faculty of Pharmacy, Alexandria University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alexandria University
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ahmed I ElMallah, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0106922
Identifier Type: -
Identifier Source: org_study_id